The Drug Regulatory Authority of Pakistan (DRAP) expressed concern over the quality and banned the sale of a popular blood thinner.
Manufactured by Wenovo Pharmaceuticals in Taxila, batch 263 of Nabaxo 10 mg tablets failed quality testing at the Drug Testing Lab in Rawalpindi.
Nabaxo, containing the active ingredient Rivaroxaban, is prescribed for preventing blood clots in conditions like thrombosis and pulmonary embolism.
DRAP has directed the company to halt supply and recall the defective batch immediately.
Chemists and distributors have been instructed to stop selling the tablets and return existing stock. Doctors and patients are advised to avoid using the affected batch to ensure treatment safety.
Regulatory field forces have been deployed to monitor markets, ensuring removal of the defective batch and identifying counterfeit versions. Distributors have been urged to report any remaining stock promptly to protect public health.
Earlier to this, DRAP conducted a crackdown against fake imported medicines and barred patients from using or purchasing the injection – Rhophylac 300.
In its product recall alert, DRAP warned patients to avoid the use of the human anti-D immunoglobulin drug ‘Rhophylac’, as the sample label of the injection – manufactured by Swiss company CSL Behring – printed incorrect details.
The KP Drug Inspector and a Karachi-based pharmaceutical company have reported the circulation of fake ‘Rhophylac’ injections in the market.
Source: ARY News
